Medscape

Emicizumab Replaces Factor VIII Function in Hemophilia A

BERLIN, GERMANY — Once-weekly subcutaneous administration of emicizumab (Roche) as prophylaxis reduced or prevented bleeds in people with hemophilia A and inhibitors to factor VIII. More than half of ...
clinicaladvisor.com

Recombinant factor VIII for hemophilia A

Active ingredient: Antihemophilic Factor (recombinant): nominally 250 IU, 500 IU, 1,000 IU, or 2,000 IU per vial; powder for IV infusion after reconstitution; plasma/ albumin-free; preservative-free; ...
Monthly Prescribing Reference

Altuviiio Approved as Once-Weekly Factor VIII Therapy for Hemophilia A

Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. The Food and Drug Administration (FDA) has approved Altuviiio ™ (antihemophilic factor [recombinant] ...
Healio

Valoctocogene roxaparvovec shows durable factor VIII activity in hemophilia A

Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec conferred sustained bleeding control at 2 years among a cohort of men with severe ...
MedPage Today

Current Landscape of Factor VIII and IX Inhibitor Testing in Hemophilia

Hemophilia A and B are X-linked bleeding disorders characterized by partial or complete absence of clotting factors VIII and IX (FVIII and FIX, respectively). FVIII and FIX are critical coagulation ...
The American Journal of Managed Care

FDA Approves Hemlibra for Hemophilia A With or Without Factor VIII Inhibitors

With its new FDA approval, Hemlibra (emicizumab-kxwh), a bispecific factor IXa- and factor X-directed antibody, has become the first prophylactic treatment for patients with hemophilia A with or ...
The American Journal of Managed Care

Patients With Hemophilia A, With or Without Factor VIII, Benefitted from Emicizumab in HAVEN Trials

Trial results show that patients with hemophilia A with or without factor VIII inhibitors treated with emicizumab-kxwh every 4 weeks can have clinically meaningful control of bleeding. Drug maker ...
Healio

Gene therapy increases factor VIII activity, reduces bleeding in severe hemophilia A

Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...
MedPage Today

Efanesoctocog Alfa Prevented Bleeding in Kids With Severe Hemophilia A

Once-weekly prophylaxis with efanesoctocog alfa (Altuviiio) led to high sustained factor VIII activity and was effective in preventing bleeding among children with severe hemophilia A, the phase III ...
Business Wire

FDA Grants Priority Review to Genentech’s HEMLIBRA (emicizumab-kxwh) for People with Hemophilia A without Factor VIII Inhibitors | Business Wire

In the HAVEN 3 study, adults and adolescents aged 12 years or older with hemophilia A without factor VIII inhibitors who received HEMLIBRA prophylaxis every week or every two weeks showed a 96 percent ...
Yahoo Finance

Hemophilia A (Factor VIII Deficiency) Global Clinical Trials Market Review 2025: Hemlibra Demonstrates Exercise-Related Bleeding Prevention as Pfizer Reports Positive Phase III ...

Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The "Hemophilia A (Factor VIII Deficiency) - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This ...
Business Wire

Chugai’s Hemlibra Receives Approval for Severe Hemophilia A Without Factor VIII Inhibitors from the European Commission

TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche received the decision from the European Commission confirming that Hemlibra ® (emicizumab) , a ...